Free Trial
OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Enzon Pharmaceuticals logo
$0.11 +0.01 (+6.71%)
As of 09:44 AM Eastern

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Key Stats

Today's Range
$0.10
$0.11
50-Day Range
$0.09
$0.17
52-Week Range
$0.06
$0.24
Volume
2,000 shs
Average Volume
80,543 shs
Market Capitalization
$8.15 million
P/E Ratio
10.99
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Remove Ads

Enzon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

ENZN MarketRank™: 

Enzon Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Enzon Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enzon Pharmaceuticals is 10.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enzon Pharmaceuticals is 10.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.42.

  • Read more about Enzon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of Enzon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzon Pharmaceuticals has recently decreased by 12.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enzon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enzon Pharmaceuticals does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Enzon Pharmaceuticals is 1,201.20%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Enzon Pharmaceuticals' dividend.
  • Percentage of Shares Shorted

    0.01% of the float of Enzon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzon Pharmaceuticals has recently decreased by 12.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enzon Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enzon Pharmaceuticals this week, compared to 0 articles on an average week.
Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENZN Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
Enzon Stock Hits New 52-Week Low (ENZN)
Ibnsina Pharma Co (ISPH)
See More Headlines

ENZN Stock Analysis - Frequently Asked Questions

Enzon Pharmaceuticals' stock was trading at $0.1561 at the beginning of the year. Since then, ENZN stock has decreased by 29.7% and is now trading at $0.1098.
View the best growth stocks for 2025 here
.

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) announced its quarterly earnings data on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share for the quarter.

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

Last Earnings
4/30/2020
Today
4/01/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
10.99
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.37 million
Pretax Margin
5,103.85%

Debt

Sales & Book Value

Annual Sales
$30,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
73,918,000
Market Cap
$8.15 million
Optionable
Not Optionable
Beta
0.26

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:ENZN) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners